249 related articles for article (PubMed ID: 26944820)
1. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
Hoyer-Kuhn H; Franklin J; Allo G; Kron M; Netzer C; Eysel P; Hero B; Schoenau E; Semler O
J Musculoskelet Neuronal Interact; 2016 Mar; 16(1):24-32. PubMed ID: 26944820
[TBL] [Abstract][Full Text] [Related]
2. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
[TBL] [Abstract][Full Text] [Related]
3. TBS as a Tool to Differentiate the Impact of Antiresorptives onCortical and Trabecular Bone in Children With OsteogenesisImperfecta.
Rehberg M; Winzenrieth R; Hoyer-Kuhn H; Duran I; Schoenau E; Semler O
J Clin Densitom; 2019; 22(2):229-235. PubMed ID: 30309730
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
Lin X; Hu J; Zhou B; Wang X; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1873-1882. PubMed ID: 38181430
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Bone Mineral Density on Quality of Life in Patients with Osteogenesis Imperfecta during Treatment with Denosumab.
Hoyer-Kuhn H; Stark C; Franklin J; Schoenau E; Semler O
Pediatr Endocrinol Rev; 2017 Nov; 15(Suppl 1):123-129. PubMed ID: 29292876
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.
Orwoll ES; Shapiro J; Veith S; Wang Y; Lapidus J; Vanek C; Reeder JL; Keaveny TM; Lee DC; Mullins MA; Nagamani SC; Lee B
J Clin Invest; 2014 Feb; 124(2):491-8. PubMed ID: 24463451
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI.
Trejo P; Rauch F; Ward L
J Musculoskelet Neuronal Interact; 2018 Mar; 18(1):76-80. PubMed ID: 29504582
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J; Lin X; Sun L; Zhang Q; Jiang Y; Wang O; Xing X; Xia W; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1827-1836. PubMed ID: 38198649
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
12. Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial.
Dimai HP; Ljuhar R; Ljuhar D; Norman B; Nehrer S; Kurth A; Fahrleitner-Pammer A
Skeletal Radiol; 2019 Jul; 48(7):1023-1032. PubMed ID: 30506302
[TBL] [Abstract][Full Text] [Related]
13. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Rauch F; Munns C; Land C; Glorieux FH
J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
[TBL] [Abstract][Full Text] [Related]
15. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
16. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
17. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
18. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.
Glorieux FH; Devogelaer JP; Durigova M; Goemaere S; Hemsley S; Jakob F; Junker U; Ruckle J; Seefried L; Winkle PJ
J Bone Miner Res; 2017 Jul; 32(7):1496-1504. PubMed ID: 28370407
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
Aström E; Jorulf H; Söderhäll S
Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
[TBL] [Abstract][Full Text] [Related]
20. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]